Geron Stock Today
| GERN Stock | USD 2.56 0.23 8.24% |
PerformanceVery Weak
| Odds Of DistressLow
|
Geron is selling at 2.56 as of the 16th of February 2025; that is 8.24% down since the beginning of the trading day. The stock's open price was 2.79. Geron has less than a 14 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of June 1996 | Category Healthcare | Classification Health Care |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. The company has 604.5 M outstanding shares of which 74.57 M shares are currently shorted by private and institutional investors with about 7.14 trading days to cover. More on Geron
Moving together with Geron Stock
Moving against Geron Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Geron Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Research President | Joseph MD | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGeron can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Geron's financial leverage. It provides some insight into what part of Geron's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Geron (GERN) is traded on NASDAQ Exchange in USA. It is located in 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404 and employs 141 people. Geron is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.55 B. Geron conducts business under Biotechnology sector and is part of Health Care industry. The entity has 604.5 M outstanding shares of which 74.57 M shares are currently shorted by private and institutional investors with about 7.14 trading days to cover.
Geron currently holds about 219.29 M in cash with (167.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58.
Check Geron Probability Of Bankruptcy
Ownership AllocationGeron has a total of 604.5 Million outstanding shares. The majority of Geron outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Geron to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Geron. Please pay attention to any change in the institutional holdings of Geron as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Geron Ownership Details
Geron Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Fmr Inc | 2024-09-30 | 15 M | |
| Geode Capital Management, Llc | 2024-09-30 | 13.1 M | |
| Wellington Management Company Llp | 2024-09-30 | 12.7 M | |
| Jefferies Financial Group Inc | 2024-09-30 | 9.7 M | |
| Deep Track Capital, Lp | 2024-09-30 | 7.6 M | |
| Eventide Asset Management, Llc | 2024-09-30 | 7.1 M | |
| Woodline Partners Lp | 2024-09-30 | 7 M | |
| T. Rowe Price Associates, Inc. | 2024-09-30 | 7 M | |
| Boxer Capital Llc | 2024-09-30 | 6 M | |
| Blackrock Inc | 2024-09-30 | 48.6 M | |
| Rtw Investments, Llc | 2024-09-30 | 44.1 M |
Geron Historical Income Statement
Geron Stock Against Markets
Geron Corporate Management
| Andrew Grethlein | Executive VP of Devel. and Technical Operations | Profile | |
| Faye MD | Executive Officer | Profile | |
| Stephen JD | Chief VP | Profile | |
| Aron Feingold | Vice Communications | Profile | |
| James MBA | Executive Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 171.384 | Return On Assets | Return On Equity |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.